

Special Issue

Purposing and Repurposing of Antimalarial Agents

Message from the Guest Editors

Malaria remains one of the leading causes of morbidity and mortality in tropical areas. Increasing resistance to the currently available antimalarial drugs has made the need to develop new and efficient agents even more urgent. Practically all currently used antimalarial drugs were developed directly or indirectly from two naturally occurring substances: quinine and artemisinin. Derivatization of clinically approved antimalarial drugs is still a popular strategy in the search of novel antiparasmodial agents.

Finding novel therapeutic indications for already approved drugs is one of possible strategies in the search of novel medicines. Antimalarial drugs and/or their derivatives are useful in the treatment of autoimmune diseases, parasitemia, and tuberculosis.

Contributions to this Special Issue may cover the rational design and synthesis of novel compounds with antiparasmodial activity or derivatives of known antimalarial agents with antimalarial (purposing) or other applications (repurposing). Short communications, original research papers or review articles are welcomed.

Guest Editors

Prof. Dr. Branka Zorc


Faculty of Pharmacy and Biochemistry, University of Zagreb, A.
Kovačića 1, 10 000 Zagreb, Croatia

Prof. Dr. Zrinka Rajić

Department of Medicinal Chemistry, Faculty of Pharmacy and
Biochemistry, University of Zagreb, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (31 July 2020)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/29219

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).